Publications - Laurence J . Miller, M.D.

Back to Research Profile

1. Dong M, Miller LJ. Effects of pH and temperature on photoaffinity labeling of Family B G protein-coupled receptors. Regul Pept 2009 Nov 27; 158(1-3):110-5. Epub 2009 May 18.
   View PubMed
2. Harikumar KG, Simms J, Christopoulos G, Sexton PM, Miller LJ. Molecular Basis of Association of Receptor Activity-Modifying Protein 3 with the Family B G Protein-Coupled Secretin Receptor. Biochemistry 2009 Nov 13. [Epub ahead of print]
   View PubMed
3. Chen Q, Pinon DI, Miller LJ, Dong M. Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem 2009 Oct 08. [Epub ahead of print]
   View PubMed
4. Dong M, Cox RF, Miller LJ. Juxtamembranous region of the amino terminus of the family B G protein-coupled calcitonin receptor plays a critical role in small-molecule agonist action. J Biol Chem 2009 Aug 14; 284(33):21839-47. Epub 2009 May 15.
   View PubMed
5. Gao F, Harikumar KG, Dong M, Lam PC, Sexton PM, Christopoulos A, Bordner A, Abagyan R, Miller LJ. Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor. Mol Pharmacol 2009 Aug; 76(2):264-74. Epub 2009 May 08.
   View PubMed
6. Korner M, Miller LJ. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol 2009 Aug; 175(2):461-72. Epub 2009 Jul 02.
   View PubMed
7. Korner M, Waser B, Reubi JC, Miller LJ. CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumors. J Cell Mol Med 2009 Jul 20. [Epub ahead of print]
   View PubMed
8. Dong M, Lam PC, Pinon DI, Abagyan R, Miller LJ. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling. Biochemistry 2009 Jun 16; 48(23):5303-12.
   View PubMed
9. Akgun E, Korner M, Gao F, Harikumar KG, Waser B, Reubi JC, Portoghese PS, Miller LJ. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem 2009 Apr 9; 52(7):2138-47.
   View PubMed
10. Zheng Y, Akgun E, Harikumar KG, Hopson J, Powers MD, Lunzer MM, Miller LJ, Portoghese PS. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J Med Chem 2009 Jan 22; 52(2):247-58.
    View PubMed
11. Simms J, Hall NE, Lam PH, Miller LJ, Christopoulos A, Abagyan R, Sexton PM. Homology modeling of GPCRs. Methods Mol Biol 2009; 552:97-113.
    View PubMed
12. Harikumar KG, Miller LJ. Application of fluorescence resonance energy transfer techniques to establish ligand-receptor orientation. Methods Mol Biol 2009; 552:293-304.
    View PubMed
13. Harikumar KG, Miller LJ. Use of fluorescence indicators in receptor ligands. Methods Mol Biol 2009; 552:279-91.
    View PubMed
14. Harikumar KG, Morfis MM, Sexton PM, Miller LJ. Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J Mol Neurosci 2008 Nov; 36(1-3):279-85. Epub 2008 Apr 10.
    View PubMed
15. Harikumar KG, Miller LJ. Monitoring the state of cholecystokinin receptor oligomerization after ligand binding using decay of time-resolved fluorescence anisotropy. Ann N Y Acad Sci 2008 Nov; 1144:21-7.
    View PubMed
16. Miller LJ. Informed development of drugs acting at family B G protein-coupled receptors. Ann N Y Acad Sci 2008 Nov; 1144:203-9.
    View PubMed
17. Harikumar KG, Happs RM, Miller LJ. Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor. Biochim Biophys Acta 2008 Nov; 1778(11):2555-63. Epub 2008 Jul 17.
    View PubMed
18. Dong M, Pinon DI, Miller LJ. Exploration of the endogenous agonist mechanism for activation of secretin and VPAC1 receptors using synthetic glycosylated peptides. J Mol Neurosci 2008 Nov; 36(1-3):254-9. Epub 2008 Apr 12.
    View PubMed
19. Miller LJ. G protein-coupled receptor structures, molecular associations, and modes of regulation. Ann N Y Acad Sci 2008 Nov; 1144:1-5.
    View PubMed
20. Harikumar KG, Gao F, Pinon DI, Miller LJ. Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor. Biochemistry 2008 Sep 9; 47(36):9574-81. Epub 2008 Aug 13.
    View PubMed
21. Wu SV, Harikumar KG, Burgess RJ, Reeve JR Jr, Miller LJ. Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation. Am J Physiol Gastrointest Liver Physiol 2008 Sep; 295(3):G641-7.
    View PubMed
22. Gao F, Sexton PM, Christopoulos A, Miller LJ. Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor. Bioorg Med Chem Lett 2008 Aug 1; 18(15):4401-4. Epub 2008 Jun 20.
    View PubMed
23. Dong M, Lam PC, Pinon DI, Sexton PM, Abagyan R, Miller LJ. Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding. Mol Pharmacol 2008 Aug; 74(2):413-22. Epub 2008 May 08.
    View PubMed
24. Kumar M, Reeve JR Jr, Hu W, Miller LJ, Keire DA. The micelle-associated 3D structures of Boc-Y(SO3)-Nle-G-W-Nle-D-2-phenylethylester (JMV-180) and CCK-8(s) share conformational elements of a calculated CCK1 receptor-bound model. J Med Chem 2008 Jul 10; 51(13):3742-54. Epub 2008 Jun 10.
    View PubMed
25. Miller LJ, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther 2008 Jul; 119(1):83-95. Epub 2008 May 11.
    View PubMed
26. Dong M, Gao F, Pinon DI, Miller LJ. Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol 2008 Jun; 22(6):1489-99. Epub 2008 Mar 27.
    View PubMed
27. Korner MU, Hayes GM, Carrigan PE, Rehmann R, Miller LJ, Reubi JC. Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue. Mod Pathol 2008 Apr; 21(4):387-95. Epub 2008 Jan 25.
    View PubMed
28. Bingham JL, Carrigan PE, Miller LJ, Srinivasan S. Extent and diversity of human alternative splicing established by complementary database annotation and microarray analysis. OMICS 2008 Mar; 12(1):83-92.
    View PubMed
29. Tokunaga H, Matsuura B, Dong M, Miller LJ, Ueda T, Furukawa S, Hiasa Y, Onji M. Mutational analysis of predicted intracellular loop domains of human motilin receptor. Am J Physiol Gastrointest Liver Physiol 2008 Feb; 294(2):G460-6. Epub 2007 Nov 21.
    View PubMed
30. Carrigan PE, Hentz JG, Gordon G, Morgan JL, Raimondo M, Anbar AD, Miller LJ. Distinctive heavy metal composition of pancreatic juice in patients with pancreatic carcinoma. Cancer Epidemiol Biomarkers Prev 2007 Dec; 16(12):2656-63.
    View PubMed
31. Harikumar KG, Lam PC, Dong M, Sexton PM, Abagyan R, Miller LJ. Fluorescence resonance energy transfer analysis of secretin docking to its receptor: mapping distances between residues distributed throughout the ligand pharmacophore and distinct receptor residues. J Biol Chem 2007 Nov 9; 282(45):32834-43. Epub 2007 Sep 07.
    View PubMed
32. Harikumar KG, Pinon DI, Miller LJ. Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor. J Biol Chem 2007 Oct 19; 282(42):30363-72. Epub 2007 Aug 28.
    View PubMed
33. Hayes GM, Carrigan PE, Dong M, Reubi JC, Miller LJ. A novel secretin receptor splice variant potentially useful for early diagnosis of pancreatic carcinoma. Gastroenterology 2007 Sep; 133(3):853-61. Epub 2007 Jun 20.
    View PubMed
34. Lisenbee CS, Harikumar KG, Miller LJ. Mapping the architecture of secretin receptors with intramolecular fluorescence resonance energy transfer using acousto-optic tunable filter-based spectral imaging. Mol Endocrinol 2007 Aug; 21(8):1997-2008. Epub 2007 May 15.
    View PubMed
35. Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, Abagyan R, Miller LJ. Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor. Mol Pharmacol 2007 Aug; 72(2):280-90. Epub 2007 May 02.
    View PubMed
36. Miller LJ, Dong M, Harikumar KG, Gao F. Structural basis of natural ligand binding and activation of the Class II G-protein-coupled secretin receptor. Biochem Soc Trans 2007 Aug; 35(Pt 4):709-12.
    View PubMed
37. Dong M, Ding XQ, Thomas SE, Gao F, Lam PC, Abagyan R, Miller LJ. Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction. Biochemistry 2007 Apr 17; 46(15):4522-31. Epub 2007 Mar 24.
    View PubMed
38. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007 Mar 1; 67(5):2072-80.
    View PubMed
39. Miller LJ, Dong M, Harikumar KG, Lisenbee CS. Biochemical and cell biological mechanisms of cholecystokinin receptor regulation. Curr Top Med Chem 2007; 7(12):1166-72.
    View PubMed
40. Harikumar KG, Dong M, Cheng Z, Pinon DI, Lybrand TP, Miller LJ. Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function. Biochemistry 2006 Dec 12; 45(49):14706-16.
    View PubMed
41. Korner M, Hayes GM, Rehmann R, Zimmermann A, Scholz A, Wiedenmann B, Miller LJ, Reubi JC. Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma. J Hepatol 2006 Dec; 45(6):825-35. Epub 2006 Jul 28.
    View PubMed
42. Harikumar KG, Pinon DI, Miller LJ. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors. J Biol Chem 2006 Sep 15; 281(37):27072-80. Epub 2006 Jul 20.
    View PubMed
43. Lisenbee CS, Miller LJ. Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Biochemistry 2006 Jul 11; 45(27):8216-26.
    View PubMed
44. Dong M, Hosohata K, Pinon DI, Muthukumaraswamy N, Miller LJ. Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling. Mol Endocrinol 2006 Jul; 20(7):1688-98. Epub 2006 Mar 02.
    View PubMed
45. Dong M, Pinon DI, Asmann YW, Miller LJ. Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharmacol 2006 Jul; 70(1):206-13. Epub 2006 Mar 10.
    View PubMed
46. Dong M, Miller LJ. Molecular approximation between residue 10 of secretin and its receptor demonstrated by photoaffinity labeling. Ann N Y Acad Sci 2006 Jul; 1070:243-7.
    View PubMed
47. Dong M, Miller LJ. Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor. Ann N Y Acad Sci 2006 Jul; 1070:248-64.
    View PubMed
48. Matsuura B, Dong M, Naik S, Miller LJ, Onji M. Differential contributions of motilin receptor extracellular domains for peptide and non-peptidyl agonist binding and activity. J Biol Chem 2006 May 5; 281(18):12390-6. Epub 2006 Mar 10.
    View PubMed
49. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res 2006 Apr 1; 66(7):3819-27.
    View PubMed
50. Harikumar KG, Pinon DI, Miller LJ. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor. Biosci Rep 2006 Apr; 26(2):89-100.
    View PubMed
51. Takeshita E, Matsuura B, Dong M, Miller LJ, Matsui H, Onji M. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol 2006 Mar; 41(3):223-30.
    View PubMed
52. Hadac EM, Dawson ES, Darrow JW, Sugg EE, Lybrand TP, Miller LJ. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. J Med Chem 2006 Feb 9; 49(3):850-63.
    View PubMed
53. Harikumar KG, Hosohata K, Pinon DI, Miller LJ. Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor. J Biol Chem 2006 Feb 3; 281(5):2543-50. Epub 2005 Nov 30.
    View PubMed
54. Harikumar KG, Morfis MM, Lisenbee CS, Sexton PM, Miller LJ. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors. Mol Pharmacol 2006 Jan; 69(1):363-73. Epub 2005 Oct 21.
    View PubMed
55. Korner M, Hayes GM, Rehmann R, Zimmermann A, Friess H, Miller LJ, Reubi JC. Secretin receptors in normal and diseased human pancreas - Marked reduction of receptor binding in ductal neoplasia. Am J Pathol 2005 Oct; 167(4):959-68.
    View PubMed
56. Pham V, Dong MQ, Wade JD, Miller LJ, Morton CJ, Ng H, Parker MW, Sexton PM. Insights into interactions between the alpha-helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling. J Biol Chem 2005 Aug 5; 280(31):28610-22.
    View PubMed
57. Dong MQ, Pinon DI, Miller LJ. Insights into the structure and molecular basis of ligand docking to the G protein-coupled secretin receptor using charge-modified amino-terminal agonist probes. Molecular Endocrinology 2005 Jul; 19(7):1821-36.
    View PubMed
58. Dong M, Hadac EM, Pinon DI, Miller LJ. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations. Mol Pharmacol 2005 Jun; 67(6):1892-900.
    View PubMed
59. Matsuura B, Dong M, Coulie B, Pinon DI, Miller LJ. Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog. Journal of Pharmacology & Experimental Therapeutics 2005 Jun; 313(3):1101-8.
    View PubMed
60. Harikumar KG, Miller LJ. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor. J Biol Chem 2005 May 13; 280(19):18631-5. Epub 2005 Mar 09.
    View PubMed
61. Cheng ZJ, Harikumar KG, Ding WQ, Holicky EL, Miller LJ. Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. Cancer Lett 2005 May 10; 222(1):95-105.
    View PubMed
62. Dong MQ, Liu GM, Pinon DI, Miller LJ. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Biochemistry 2005 May 3; 44(17):6693-700.
    View PubMed
63. Lisenbee CS, Dong MQ, Miller LJ. Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor. J Biol Chem 2005 Apr 1; 280(13):12330-8.
    View PubMed
64. Harikumar KG, Puri V, Singh RD, Hanada K, Pagano RE, Miller LJ. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor. J Biol Chem 2005 Jan 21; 280(3):2176-85. Epub 2004 Nov 10.
    View PubMed
65. Harikumar KG, Clain J, Pinon DI, Dong M, Miller LJ. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy. J Biol Chem 2005 Jan 14; 280(2):1044-50. Epub 2004 Nov 01.
    View PubMed
66. Asmann YW, Dong MQ, Miller LJ. Functional characterization and purification of the secretin receptor expressed in baculovirus-infected insect cells. Regul Pept 2004 Dec 15; 123(1-3):217-23.
    View PubMed
67. Arlander SJH, Dong MQ, Ding XQ, Pinon DI, Miller LJ. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist. Mol Pharmacol 2004 Sep; 66(3):545-52.
    View PubMed
68. Dong MQ, Pinon DI, Cox RF, Miller LJ. Molecular approximation between a residue in the amino-terminal region of calcitonin and the third extracellular loop of the class B G protein-coupled calcitonin receptor. J Biol Chem 2004 Jul 23; 279(30):31177-82.
    View PubMed
69. Conti AM, Brimijoin S, Miller LJ, Windebank AJ. Suppression of neurite outgrowth by high-dose nerve growth factor is independent of functional p75NTR receptors. Neurobiol Dis 2004 Feb; 15(1):106-14.
    View PubMed
70. Dong MQ, Li ZJ, Pinon DI, Lybrand TP, Miller LJ. Spatial approximation between the amino terminus of a peptide agonist and the top of the sixth transmembrane segment of the secretin receptor. J Biol Chem 2004 Jan 23; 279(4):2894-903.
    View PubMed
71. Dong MQ, Pinon DI, Cox RF, Miller LJ. Importance of the amino terminus in secretin family G protein-coupled receptors - Intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor. J Biol Chem 2004 Jan 9; 279(2):1167-75.
    View PubMed
72. Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer. Mol Pharmacol 2004 Jan; 65(1):28-35.
    View PubMed
73. Cheng ZJ, Harikumar KG, Holicky EL, Miller LJ. Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth. J Biol Chem 2003 Dec 26; 278(52):52972-9. Epub 2003 Oct 08.
    View PubMed
74. Dong MQ, Li ZJ, Zang MQ, Pinon DI, Lybrand TP, Miller LJ. Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor - Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor. J Biol Chem 2003 Nov 28; 278(48):48300-12.
    View PubMed
75. Fernandez-Zapico ME, Mladek A, Ellenrieder V, Folch-Puy E, Miller L, Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J 2003 Sep 15; 22(18):4748-58.
    View PubMed
76. Zang MW, Dong MQ, Pinon DI, Ding XQ, Hadac EM, Li ZJ, Lybrand TP, Miller LJ. Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. Mol Pharmacol 2003 May; 63(5):993-1001.
    View PubMed
77. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003 Mar; 55(1):167-94.
    View PubMed
78. Ding XQ, Dolu V, Hadac EM, Schuetz M, Miller LJ. Disulfide bond structure and accessibility of cysteines in the ectodomain of the cholecystokinin receptor: Specific mono-reactive receptor constructs examine charge-sensitivity of loop regions. Receptors & Channels 2003 Mar-Apr; 9(2):83-91.
    View PubMed
79. Ding WQ, Dong MQ, Ninova D, Holicky EL, Stegall MD, Miller LJ. Forskolin suppresses insulin gene transcription in islet beta-cells through a protein kinase A-independent pathway. Cell Signal 2003 Jan; 15(1):27-35.
    View PubMed
80. Miller LJ, Lybrand TP. Molecular basis of agonist binding to the type A cholecystokinin receptor. Pharmacology & Toxicology 2002 Dec; 91(6):282-5.
    View PubMed
81. Dawson ES, Henne RM, Miller LJ, Lybrand TP. Moleular models for cholecystokinin-A receptor. Pharmacology & Toxicology 2002 Dec; 91(6):290-6.
    View PubMed
82. Harikumar KG, Miller LJ. Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor. Pharmacol Toxicol 2002 Dec; 91(6):286-9.
    View PubMed
83. Dong MQ, Pinon DI, Miller LJ. Development of a biologically active secretin analogue incorporating a radioiodinatable photolabile p-(4-hydroxybenzoyl)phenylalanine in position 10. Regul Pept 2002 Nov 15; 109(1-3):181-7.
    View PubMed
84. Dong MQ, Zang MW, Pinon DI, Li ZJ, Lybrand TP, Miller LJ. Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. Mol Endocrinol 2002 Nov; 16(11):2490-501.
    View PubMed
85. Chari ST, Yadav D, Smyrk TC, DiMagno EP, Miller LJ, Raimondo M, Clain JE, Norton IA, Pearson RK, Petersen BT, Wiersema MJ, Farnell MB, Sarr MG. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002 Nov; 123(5):1500-7.
    View PubMed
86. Ding WQ, Cheng ZJ, McElhiney J, Kuntz SM, Miller LJ. Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res 2002 Sep 15; 62(18):5223-9.
    View PubMed
87. Harikumar KG, Pinon DI, Wessels WS, Prendergast FG, Miller LJ. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor. J Biol Chem 2002 May 24; 277(21):18552-60. Epub 2002 Mar 13.
    View PubMed
88. Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller LJ. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Mol Pharmacol 2002 May; 61(5):1041-52.
    View PubMed
89. Matsuura B, Dong MQ, Miller LJ. Differential determinants for peptide and non-peptidyl ligand binding to the motilin receptor - Critical role of second extracellular loop for peptide binding and action. J Biol Chem 2002 Mar 22; 277(12):9834-9.
    View PubMed
90. Ding WQ, Kuntz SM, Miller LJ. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: Role of reduced cellular U2AF35 and a suboptimal 3 '-splicing site leading to retention of the fourth intron. Cancer Res 2002 Feb 1; 62(3):947-52.
    View PubMed
91. Ding WQ, Kuntz S, Bohmig M, Wiedenmann B, Miller LJ. Dominant negative action of an abnormal secretin receptor arising from mRNA missplicing in a gastrinoma. Gastroenterology 2002 Feb; 122(2):500-11.
    View PubMed
92. Dong MQ, Miller LJ. Molecular pharmacology of the secretin receptor. Receptors & Channels 2002; 8(3-4 Special Issue SI):189-200.
    View PubMed
93. Ding WQ, Miller LJ. Signaling from novel splice variants of hormone receptors in cancer. International Journal of Gastrointestinal Cancer 2002; 31(1-3):31-9.
    View PubMed
94. Ding WQ, Dong M, Ninova D, Holicky EL, Stegall MD, Miller LJ. Forskolin surpresses insulin gene transcription in islet beta cells through a protein kinase A-independent pathway. Cellular Signaling 2002; 15:27-35.
95. Cheng ZJ, Miller LJ. Agonist-dependent dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer. J Biol Chem 2001 Dec 21; 276(51):48040-7.
    View PubMed
96. Shin DM, Luo X, Wilkie TM, Miller LJ, Peck AB, Humphreys-Beher MG, Muallem S. Polarized expression of G protein-coupled receptors and an all-or-none discharge of Ca2+ pools at initiation sites of [Ca2+]i waves in polarized exocrine cells. J Biol Chem 2001 Nov 23; 276(47):44146-56.
    View PubMed
97. Ding WQ, Holicky E, Miller LJ. Glucose and forskolin regulate IAPP gene expression through different signal transduction pathways. American Journal of Physiology - Endocrinology & Metabolism 2001 Nov; 281(5):E938-E945.
    View PubMed
98. Coulie B, Matsuura B, Dong MQ, Hadac EM, Pinon DI, Feighner SD, Howard AD, Miller LJ. Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling. J Biol Chem 2001 Sep 21; 276(38):35518-35522.
    View PubMed
99. Ding XQ, Ding WQ, Miller LJ. Receptor biology and signal transduction. Curr Opin Gastroenterol 2001 Sep; 17(5):410-5.
    View PubMed
100. Roettger BF, Hellen EH, Burghardt TP, Miller LJ. Multiple ligand and cell-dependent states of lateral mobility of plasmalemmal G protein-coupled cholecystokinin receptors. Journal of Fluorescence 2001 Sep; 11(3):237-46.
101. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001 Sep; 121(3):640-5.
     View PubMed
102. Nardone G, Holicky EL, Uhl JR, Sabatino L, Staibano S, Rocco A, Colantuoni V, Manzo BA, Romano M, Budillon G, Cockerill FR, Miller LJ. In vivo and in vitro studies of cytosolic phospholipase A(2) expression in Helicobacter pylori infection. Infect Immun 2001 Sep; 69(9):5857-5863.
     View PubMed
103. Ding XQ, Miller LJ. Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies. Peptides 2001 Aug; 22(8):1223-1228.
     View PubMed
104. Holicky EL, Hadac EM, Ding XQ, Miller LJ. Molecular characterization and organ distribution of type A and B cholecystokinin receptors in cynomolgus monkey. Am J Physiol Gastrointest Liver Physiol 2001 Aug; 281(2):G507-14.
     View PubMed
105. Jiang SW, Dong M, Trujillo MA, Miller LJ, Eberhardt NL. DNA binding of TEA/ATTS domain factors is regulated by protein kinase C phosphorylation in human choriocarcinoma cells. J Biol Chem 2001 Jun 29; 276(26):23464-70.
     View PubMed
106. Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe. J Biol Chem 2001 Feb 9; 276(6):4236-4244.
     View PubMed
107. Tietz PS, Hadac EM, Miller LJ, LaRusso NF. Upregulation of secretin receptors on cholangiocytes after bile duct ligation. Regul Pept 2001 Feb 2; 97(1):1-6.
     View PubMed
108. Miller LJ, Ding XQ. Insights into the molecular basis of ligand binding by the cholecystokinin receptor. Pancreatology 2001; 1(4):336-42.
     View PubMed
109. Ding XQ, Rao RV, Kuntz SM, Holicky EL, Miller LJ. Impaired resensitization and recycling of the cholecystokinin receptor by co-expression of its second intracellular loop. Mol Pharmacol 2000 Dec; 58(6):1424-33.
     View PubMed
110. Rao RV, Holicky EL, Kuntz SM, Miller LJ. CCK receptor phosphorylation exposes regulatory domains affecting phosphorylation and receptor trafficking. Am J Physiol Cell Physiol 2000 Dec; 279(6):C1986-92.
     View PubMed
111. Miller LJ, Coulie B. Characterization of the motilin receptor, a member of a new receptor family. Digestive & Liver Disease 2000 Dec; 32(Suppl 3):S223-4.
112. Asmann YW, Dong M, Ganguli S, Hadac EM, Miller LJ. Structural insights into the amino-terminus of the secretin receptor: I. Status of cysteine and cystine residues. Mol Pharmacol 2000 Nov; 58(5):911-9.
     View PubMed
113. Park CG, Ganguli SC, Pinon DI, Hadac EM, Miller LJ. Cross-chimeric analysis of selectivity of secretin and VPAC(1) receptor activation. Journal of Pharmacology & Experimental Therapeutics 2000 Nov; 295(2):682-8.
     View PubMed
114. Dong M, Asmann YW, Zang M, Pinon DI, Miller LJ. Identification of two pairs of spatially approximated residues within the carboxyl terminus of secretin and its receptor. J Biol Chem 2000 Aug 25; 275(34):26032-9.
     View PubMed
115. Dong M, Wang Y, Miller LJ. Dual contacts between peptide agonist ligands and the secretin receptor directly established by photoaffinity labeling. Ann N Y Acad Sci 2000; 921:381-6.
     View PubMed
116. Pang RT, Ng SS, Cheng CH, Holtmann MH, Miller LJ, Chow BK. Role of N-linked glycosylation on the function and expression of the human secretin receptor. Endocrinology 1999 Nov; 140(11):5102-11.
     View PubMed
117. Sternini C, Wong H, Pham T, De Giorgio R, Miller LJ, Kuntz SM, Reeve JR, Walsh JH, Raybould HE. Expression of cholecystokinin A receptors in neurons innervating the rat stomach and intestine. Gastroenterology 1999 Nov; 117(5):1136-46.
     View PubMed
118. Dong M, Wang Y, Hadac EM, Pinon DI, Holicky E, Miller LJ. Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor. J Biol Chem 1999 Jul 2; 274(27):19161-7.
     View PubMed
119. Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely. J Med Chem 1999 Jun 17; 42(12):2105-11.
     View PubMed
120. Roettger BF, Pinon DI, Burghardt TP, Miller LJ. Regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist. Am J Physiol 1999 Mar; 276(3 Pt 1):C539-47.
     View PubMed
121. Dong M, Ding XQ, Pinon DI, Hadac EM, Oda RP, Landers JP, Miller LJ. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis. J Biol Chem 1999 Feb 19; 274(8):4778-85.
     View PubMed
122. Dong M, Wang Y, Pinon DI, Hadac EM, Miller LJ. Demonstration of a direct interaction between residue 22 in the carboxyl-terminal half of secretin and the amino-terminal tail of the secretin receptor using photoaffinity labeling. J Biol Chem 1999 Jan 8; 274(2):903-9.
     View PubMed
123. Miller LJ. Molecular genetics for the pancreatologist. Curr Gastroenterol Rep 1999; 1:132-3.
     View PubMed
124. Ulrich CD 2nd, Wood P, Hadac EM, Kopras E, Whitcomb DC, Miller LJ. Cellular distribution of secretin receptor expression in rat pancreas. Am J Physiol 1998 Dec; 275(6 Pt 1):G1437-44.
     View PubMed
125. Darrow JW, Hadac EM, Miller LJ, Sugg EE. Structurally similar small molecule photoaffinity CCK-a agonists and antagonists as novel tools for directly probing 7TM receptor-ligand interactions. Bioorg Med Chem Lett 1998 Nov 17; 8(22):3127-32.
     View PubMed
126. Urrutia R, Miller LJ. Novel membrane-to-nucleus pathways in the regulation of pancreatic acinar cell function. Curr Opin Gastroenterol 1998 Sep; 14(5):369-375.
127. Ganguli SC, Park CG, Holtmann MH, Hadac EM, Kenakin TP, Miller LJ. Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. Journal of Pharmacology & Experimental Therapeutics 1998 Aug; 286(2):593-8.
     View PubMed
128. Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, Miller LJ. Direct identification of a second distinct site of contact between cholecystokinin and its receptor. J Biol Chem 1998 May 22; 273(21):12988-93.
     View PubMed
129. Smeets RL, Rao RV, van Emst-de Vries SE, De Pont JJ, Miller LJ, Willems PH. Reduced cholecystokinin receptor phosphorylation and restored signalling in protein kinase C down-regulated rat pancreatic acinar cells. Pflugers Arch 1998 Feb; 435(3):422-8.
     View PubMed
130. Ulrich CD 2nd, Holtmann M, Miller LJ. Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology 1998 Feb; 114(2):382-97.
     View PubMed
131. Marlowe KJ, Farshori P, Torgerson RR, Anderson KL, Miller LJ, McNiven MA. Changes in kinesin distribution and phosphorylation occur during regulated secretion in pancreatic acinar cells. Eur J Cell Biol 1998 Feb; 75(2):140-52.
     View PubMed
132. Urrutia R, Miller LJ, DiMagno EP. 1996 Comfort Symposium on Pancreatic Carcinogenesis. Pancreas 1998 Jan; 16(1):1-5.
     View PubMed
133. Go W, Holicky EL, Hadac EM, Rao RV, Miller LJ. Effects of mutagenesis and truncation of the carboxyl-terminus of the cholecystokinin receptor on ligand binding, signaling, and receptor internalization. Am J Physiol 1998; 275:G56-62.
     View PubMed
134. Urrutia R, Miller LJ, DiMagno EP. 1999 Cell signaling and transcription regulation in acinar epithelial cells. Curr Opin Gastroenterol 1998; 16(1):1-5.
135. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP, Miller LJ. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem 1997 Sep 26; 272(39):24393-401.
     View PubMed
136. Dong MQ, Oda RP, Strausbauch MA, Wettstein PJ, Landers JP, Miller LJ. Hydrophobic peptide mapping of clinically relevant heptahelical membrane proteins by capillary electrophoresis. Electrophoresis 1997 Sep; 18(10):1767-1774.
     View PubMed
137. Ghanekar D, Hadac EM, Holicky EL, Miller LJ. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor. Journal of Pharmacology & Experimental Therapeutics 1997 Sep; 282(3):1206-12.
     View PubMed
138. Rao RV, Hadac EM, Roettger BF, Miller LJ. Cholecystokinin-induced desensitization, receptor phosphorylation, and internalization in the CHP212 neuroblastoma cell line. J Neurochem 1997 Jun; 68(6):2356-62.
     View PubMed
139. Go WY, Roettger BF, Holicky EL, Hadac EM, Miller LJ. Quantitative dynamic multicompartmental analysis of cholecystokinin receptor movement in a living cell using dual fluorophores and reconstruction of confocal images. Anal Biochem 1997 May 1; 247(2):210-5.
     View PubMed
140. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, Miller LJ. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 1997 Mar; 51(3):357-62.
     View PubMed
141. Detoledo CF, Roettger BF, Moryswortmann C, Schmidt WE, Miller LJ. Cellular handling of unoccupied and agonist-stimulated cholecystokinin receptor determined by immunolocalization. Am J Physiol Gastrointest Liver Physiol 1997 Mar; 272(3):G 488-G 497.
142. Rao RV, Roettger BF, Hadac EM, Miller LJ. Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing Chinese hamster ovary cholecystokinin receptor cells. Mol Pharmacol 1997 Feb; 51(2):185-92.
     View PubMed
143. Alpini G, Ulrich C, Roberts S, Phillips JO, Ueno Y, Podila PV, Colegio O, Lesage GD, Miller LJ, LaRusso NF. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol Gastrointest Liver Physiol 1997 Feb; 272(2):G 289-G 297.
144. Holtmann MH, Hadac EM, Ulrich CD, Miller LJ. Molecular basis and species specificity of high affinity binding of vasoactive intestinal polypeptide by the rat secretin receptor. Journal of Pharmacology & Experimental Therapeutics 1996 Nov; 279(2):555-60.
     View PubMed
145. Holtmann MH, Roettger BF, Pinon DI, Miller LJ. Role of receptor phosphorylation in desensitization and internalization of the secretin receptor. J Biol Chem 1996 Sep 20; 271(38):23566-71.
     View PubMed
146. Ji Z, Pinon DI, Miller LJ. Development of magnetic beads for rapid and efficient metal-chelate affinity purifications. Anal Biochem 1996 Sep 5; 240(2):197-201.
     View PubMed
147. Hadac EM, Ghanekar DV, Holicky EL, Pinon DI, Dougherty RW, Miller LJ. Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation. Pancreas 1996 Aug; 13(2):130-9.
     View PubMed
148. Holtmann MH, Ganguli S, Hadac EM, Dolu V, Miller LJ. Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J Biol Chem 1996 Jun 21; 271(25):14944-9.
     View PubMed
149. Ozcelebi F, Rao RV, Holicky E, Madden BJ, McCormick DJ, Miller LJ. Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells. Similarities and differences relative to native pancreatic acinar cell receptors. J Biol Chem 1996 Feb 16; 271(7):3750-5.
     View PubMed
150. Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW Jr, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem 1996 Jan 19; 39(2):562-9.
     View PubMed
151. Katz M, Carangelo R, Miller LJ, Gorelick F. Effect of ethanol on cholecystokinin-stimulated zymogen conversion in pancreatic acinar cells. Am J Physiol Gastrointest Liver Physiol 1996 Jan; 33(1):G 171-G 175.
152. Belov L, Akhter J, Meher-Homji V, Nicholson S, Miller LJ, Morris DL. Monoclonal antibody 2C1 does not recognise the CCK-B (gastrin) receptor. Surg Res Commun 1996; 18:183-95.
153. Nardone G, Ferber IA, Miller LJ. The integrity of the cholecystokinin receptor gene in gallbladder disease and obesity. Hepatology 1995 Dec; 22(6):1751-3.
     View PubMed
154. Tietz PS, Holman RT, Miller LJ, LaRusso NF. Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry 1995 Nov 28; 34(47):15436-43.
     View PubMed
155. Ozcelebi F, Holtmann MH, Rentsch RU, Rao R, Miller LJ. Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor. Mol Pharmacol 1995 Nov; 48(5):818-24.
     View PubMed
156. Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 1995 Oct; 109(4):1375-80.
     View PubMed
157. Roettger BF, Rentsch RU, Hadac EM, Hellen EH, Burghardt TP, Miller LJ. Insulation of G protein-coupled receptor on the plasmalemmal surface of the pancreatic acinar cell. J Cell Biol 1995 Aug; 130:579-590.
     View PubMed
158. Holtmann MH, Hadac EM, Miller LJ. Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J Biol Chem 1995 Jun 16; 270(24):14394-8.
     View PubMed
159. Roettger BF, Rentsch RU, Pinon D, Holicky E, Hadac E, Larkin JM, Miller LJ. Dual pathways of internalization of the cholecystokinin receptor. J Cell Biol 1995 Mar; 128(6):1029-41.
     View PubMed
160. Ozcelebi F, Miller LJ. Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. J Biol Chem 1995 Feb 17; 270(7):3435-41.
     View PubMed
161. Sugg EE, Kimery MJ, Ding JM, Kenakin DC, Miller LJ, Queen KL, Rimele TJ. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A- 71623). J Med Chem 1995 Jan 6; 38(1):207-11.
     View PubMed
162. Lutz MP, Pinon DI, Miller LJ. A nonradioactive fluorescent gel-shift assay for the analysis of protein phosphatase and kinase activities toward protein-specific peptide substrates. Anal Biochem 1994 Aug 1; 220(2):268-74.
     View PubMed
163. Miller LJ, Hadac EM, Powers SP. Preparation of radiolabeled photolabile probes of high specific radioactivity for affinity labeling. Anal Biochem 1994 Aug 1; 220(2):434-5.
     View PubMed
164. Gaisano HY, Miller LJ, Foskett JK. Suppression of Ca2+ oscillations induced by cholecystokinin (CCK) and its analog OPE in rat pancreatic acinar cells by low-level protein kinase C activation without transition of the CCK receptor from a high- to low-affinity state. Pflugers Arch 1994 Jul; 427(5-6):455-62.
     View PubMed
165. Lutz MP, Pinon DI, Miller LJ. Characterization of protein serine/threonine phosphatases in rat pancreas and development of an endogenous substrate-specific phosphatase assay. Pancreas 1994 Jul; 9(4):418-24.
     View PubMed
166. Gaisano HY, Miller LJ. Low concentrations of protein kinase C-activating agonists suppress cholecystokinin-OPE-evoked Ca2+ mobilization in rat pancreatic acini. Pancreas 1994 Jul; 9(4):450-3.
     View PubMed
167. Alpini G, Ulrich CD 2nd, Phillips JO, Pham LD, Miller LJ, LaRusso NF. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. Am J Physiol 1994 May; 266(5 Pt 1):G922-8.
     View PubMed
168. Zhu Z, Lutz M, Gates LK, Miller LJ. Mechanisms of heterologous agonist-stimulated phosphorylation of cholecystokinin receptor. Am J Physiol 1994 Apr; 266(4 Pt 1):C904-10.
     View PubMed
169. Ulrich CD 2nd, Pinon DI, Hadac EM, Holicky EL, Chang-Miller A, Gates LK, Miller LJ. Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. Gastroenterology 1993 Nov; 105(5):1534-43.
     View PubMed
170. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G, Miller LJ. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun 1993 May 28; 193(1):204-11.
     View PubMed
171. Lutz MP, Sutor SL, Abraham RT, Miller LJ. A role for cholecystokinin-stimulated protein tyrosine phosphorylation in regulated secretion by the pancreatic acinar cell. J Biol Chem 1993 May 25; 268(15):11119-24.
     View PubMed
172. Gates LK, Ulrich CD, Miller LJ. Multiple kinases phosphorylate the pancreatic cholecystokinin receptor in an agonist-dependent manner. Am J Physiol 1993 May; 264(5 Pt 1):G840-7.
     View PubMed
173. Marino CR, Leach SD, Schaefer JF, Miller LJ, Gorelick FS. Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas. FEBS Lett 1993 Jan 18; 316(1):48-52.
     View PubMed
174. Lutz MP, Pinon DI, Gates LK, Shenolikar S, Miller LJ. Control of cholecystokinin receptor dephosphorylation in pancreatic acinar cells. J Biol Chem 1993; 268:12136-12142.
     View PubMed
175. Lutz MP, Miller LJ. Cholecystokinin receptors: radioligand binding and affinity labeling. Methods in Neurosciences 1993; 11:170-185.
176. Miller LJ. Cell-surface receptors and pancreatic acinar cell physiology. Curr Opin Gastroenterol 1993; 9:732-739.
177. Miller LJ. The biochemical characterization of the native pancreatic cholecystokinin receptor using affinity labeling approaches. Yale J Biol Med 1992 Sep-Oct; 65(5):441-8; discussion 465-9.
     View PubMed
178. Farley DR, Van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome: a collective surgical experience. Ann Surg 1992 Jun; 215:561-570.
     View PubMed
179. Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF Jr, Beinborn M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A 1992 Apr 15; 89(8):3605-9.
     View PubMed
180. Miller LJ, Hadac EM, Gates LK, Gaisano HY. Binding of a phenethyl ester analogue of cholecystokinin to the solubilized pancreatic cholecystokinin receptor: use in ligand-affinity chromatography. Biochem Biophys Res Commun 1992 Mar 16; 183(2):396-404.
     View PubMed
181. Gaisano HY, Miller LJ. Complex role of protein kinase C mediating the supramaximal inhibition of pancreatic secretion observed with cholecystokinin. Biochem Biophys Res Commun 1992; 187:498-506.
     View PubMed
182. Miller LJ. Pancreatic acinar cell physiology and function. Curr Opin Gastroenterol 1992; 8:801-807.
183. Farley DR, Van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome. Trans South Surg Assoc 1991 Dec; 103:165-174.
184. Kamath PS, Gaisano HY, Phillips SF, Miller LJ, Charboneau JW, Brown ML, Zinsmeister AR. Abnormal gallbladder motility in irritable bowel syndrome: evidence for target-organ defect. Am J Physiol 1991 Jun; 260(6 Pt 1):G815-9.
     View PubMed
185. Klueppelberg UG, Gates LK, Gorelick FS, Miller LJ. Agonist-regulated phosphorylation of the pancreatic cholecystokinin receptor. J Biol Chem 1991 Feb 5; 266(4):2403-8.
     View PubMed
186. Otterness DM, Powers SP, Miller LJ, Weinshilboum RM. 3'-phosphoadenosine-5'-phosphosulfate: photoaffinity ligand for sulfotransferase enzymes. Mol Pharmacol 1991 Jan; 39(1):34-41.
     View PubMed
187. Lennon VA, Sas DF, Busk MF, Scheithauer B, Malagelada JR, Camilleri M, Miller LJ. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991 Jan; 100(1):137-42.
     View PubMed
188. Powers SP, Foo I, Pinon D, Klueppelberg UG, Hedstrom JF, Miller LJ. Use of photoaffinity probes containing poly(ethylene glycol) spacers for topographical mapping of the cholecystokinin receptor complex. Biochemistry 1991; 30:676-682.
     View PubMed
189. Molero X, Miller LJ. The gallbladder cholecystokinin receptor exists in two guamime nucleotide-binding protein-regulated affinity states. Mol Pharmacol 1991; 39:150-156.
     View PubMed
190. Klueppelberg UG, Molero X, Barrett RW, Miller LJ. Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells. Mol Pharmacol 1990 Aug; 38(2):159-63.
     View PubMed
191. Tanaka M, Sarr MG, Miller LJ, Malagelada JR. Changes in tone of canine gallbladder measured by an electronic pneumatic barostat. Am J Physiol 1990 Aug; 259(2 Pt 1):G314-20.
     View PubMed
192. Kost LJ, Gores GJ, Sayles JM, Miller LJ, Lemasters JJ, Herman B, LaRusso NF. Lack of metabolic effects of cholecystokinin on hepatocytes. Hepatology 1990 Aug; 12(2):301-5.
     View PubMed
193. Hunter EB, Powers SP, Kost LJ, Pinon DI, Miller LJ, LaRusso NF. Physicochemical determinants in hepatic extraction of small peptides. Hepatology 1990 Jul; 12(1):76-82.
     View PubMed
194. Schjoldager B, Molero X, Miller LJ. Gallbladder CCK receptors: species differences in glycosylation of similar protein cores. Regul Pept 1990 May 21; 28(3):265-72.
     View PubMed
195. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, MacCarty RL, Ciociola A. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990 Apr; 35(4):477-80.
     View PubMed
196. Klueppelberg UG, Powers SP, Miller LJ. The efficiency of covalent labeling of the pancreatic cholecystokinin receptor using a battery of cross-linkable and photolabile probes. Receptor 1990; 1:1-11.
     View PubMed
197. Otterness DM, Powers SP, Miller LJ, Weinshilboum RM. Human liver thermostable phenol sulfotransferase: photoaffinity labeling with 2-iodo-4-azidophenol. Mol Pharmacol 1989 Dec; 36(6):856-65.
     View PubMed
198. Duong LT, Hadac EM, Miller LJ, Vlasuk GP. Purification and characterization of the rat pancreatic cholecystokinin receptor. J Biol Chem 1989 Oct 25; 264(30):17990-6.
     View PubMed
199. Klueppelberg UG, Powers SP, Miller LJ. Protease peptide mapping of affinity-labeled rat pancreatic cholecystokinin-binding proteins. Biochemistry 1989 Aug 22; 28(17):7124-9.
     View PubMed
200. Gores GJ, Kost LJ, Miller LJ, LaRusso NF. Processing of cholecystokinin by isolated liver cells. Am J Physiol 1989 Aug; 257(2 Pt 1):G242-8.
     View PubMed
201. Sas DF, Lundy JK, Miller LJ. Culture of human neoplastic gastrointestinal smooth muscle cells. In Vitro Cellular & Developmental Biology 1989 Aug; 25(8):730-6.
     View PubMed
202. Pearson RK, Hadac EM, Miller LJ. Structural analysis of a distinct subtype of CCK receptor on human gastric smooth muscle tumors. Am J Physiol 1989 Jun; 256(6 Pt 1):G1005-10.
     View PubMed
203. Klueppelberg UG, Gaisano HY, Powers SP, Miller LJ. Use of a nitrotryptophan-containing peptide for photoaffinity labeling the pancreatic cholecystokinin receptor. Biochemistry 1989 Apr 18; 28(8):3463-8.
     View PubMed
204. Schjoldager B, Molero X, Miller LJ. Functional and biochemical characterization of the human gallbladder muscularis cholecystokinin receptor. Gastroenterology 1989 Apr; 96(4):1119-25.
     View PubMed
205. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, Ciociola A. Effect of a selective 5HT3 antagonist (GR-38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34:1511-1515.
     View PubMed
206. Gaisano HY, Klueppelberg UG, Pinon D, Pfenning MA, Powers SP, Miller LJ. A novel tool for the study of cholecystokinin-stimulated pancreatic enzyme secretion. J Clin Invest 1989; 83:321-325.
     View PubMed
207. Sas D, Miller LJ. Culture behavior of healthy bovine gallbladder muscularis smooth muscle cells. Am J Physiol 1988 Nov; 255(5 Pt 1):G653-9.
     View PubMed
208. Schjoldager B, Powers SP, Miller LJ. Affinity labeling the bovine gallbladder cholecystokinin receptor using a battery of probes. Am J Physiol 1988 Nov; 255(5 Pt 1):G579-86.
     View PubMed
209. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988 Sep; 29(9):1236-43.
     View PubMed
210. Powers SP, Pinon DI, Miller LJ. Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. International Journal of Peptide & Protein Research 1988 May; 31(5):429-34.
     View PubMed
211. Klueppelberg UG, Gaisano H, Powers S, Miller LJ. Active site labeling of the pancreatic cholecystokinin receptor using a new intrinsic photoactivatable probe. Gastroenterology 1988 May; 94(PART 2):A230.
212. Schjoldager B, Shaw MJ, Powers SP, Schmalz PF, Szurszewski J, Miller LJ. Bovine gallbladder muscularis: source of a myogenic receptor for cholecystokinin. Am J Physiol 1988 Mar; 254(3 Pt 1):G294-9.
     View PubMed
213. Powers SP, Fourmy D, Gaisano H, Miller LJ. Intrinsic photoaffinity-labeling probes for cholecystokinin (CCK)-gastrin family receptors. D-Tyr-Gly(Nle28,31,pN02-Phe33) CCK-26-33. J Biol Chem 1988; 263:5295-5300.
     View PubMed
214. Miller LJ, Powers SP. Biochemical characterization of the pancreatic cholecystokinin receptor: a possible marker of cell differentiation and development. Scand J Gastroenterol Suppl 1988; 151:104-7.
     View PubMed
215. Kellow JE, Miller LJ, Phillips SF, Zinsmeister AR, Charboneau JW. Altered sensitivity of the gallbladder to cholecystokinin octapeptide in irritable bowel syndrome. Am J Physiol 1987 Nov; 253(5 Pt 1):G650-5.
     View PubMed
216. Shaw MJ, Hadac EM, Miller LJ. Preparation of enriched plasma membranes from bovine gallbladder muscularis for characterization of cholecystokinin receptors. J Biol Chem 1987 Oct 15; 262(29):14313-8.
     View PubMed
217. Pearson RK, Miller LJ, Hadac EM, Powers SP. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. J Biol Chem 1987 Oct 5; 262(28):13850-6.
     View PubMed
218. Pearson RK, Powers SP, Hadac EM, Gaisano H, Miller LJ. Establishment of a new short, protease-resistant, affinity labeling reagent for the cholecystokinin receptor. Biochem Biophys Res Commun 1987 Aug 31; 147(1):346-53.
     View PubMed
219. Kellow JE, Miller LJ, Phillips SF, Haddad AC, Zinsmeister AR, Charboneau JW. Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide. Am J Physiol 1987 Mar; 252(3 Pt 1):G345-56.
     View PubMed
220. Pearson RK, Miller LJ. Affinity labeling of a novel cholecystokinin-binding protein in rat pancreatic plasmalemma using new short probes for the receptor. J Biol Chem 1987 Jan 15; 262(2):869-76.
     View PubMed
221. Pearson RK, Miller LJ, Powers SP, Hadac EM. Biochemical characterization of the pancreatic cholecystokinin receptor using monofunctional photoactivatable probes. Pancreas 1987; 2(1):79-84.
     View PubMed
222. van Heerden JA, Smith SL, Miller LJ. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type I. Surgery 1986 Dec; 100(6):971-7.
     View PubMed
223. Pearson RK, Hadac EM, Miller LJ. Preparation and characterization of a new cholecystokinin receptor probe that can be oxidatively radioiodinated. Gastroenterology 1986 Jun; 90(6):1985-91.
     View PubMed
224. Miller LJ, Bouska JB, Go VL. Extraction of cholecystokinin peptides from biological fluids using octadecylsilane-packed cartridges. J Chromatogr 1986 May 28; 378(1):77-84.
     View PubMed
225. Gores GJ, LaRusso NF, Miller LJ. Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol 1986 Mar; 250(3 Pt 1):G344-9.
     View PubMed
226. Gores GJ, Miller LJ, LaRusso NF. Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion. Am J Physiol 1986 Mar; 250(3 Pt 1):G350-6.
     View PubMed
227. Gaisano HY, Reilly W, Go VL, Olivero D, Miller LJ. Large molecular forms of cholecystokinin circulating in humans. Pancreas 1986; 1(2):148-53.
     View PubMed
228. Tietz PS, Thistle JL, Miller LJ, LaRusso NF. Development and validation of a method for measuring the glycine and taurine conjugates of bile acids in bile by high-performance liquid chromatography. J Chromatogr 1984 Dec 12; 336(2):249-57.
     View PubMed
229. Miller LJ. Characterization of cholecystokinin receptors on human gastric smooth muscle tumors. Am J Physiol 1984 Oct; 247(4 Pt 1):G402-10.
     View PubMed
230. Miller LJ, Jardine I, Weissman E, Go VL, Speicher D. Characterization of cholecystokinin from the human brain. J Neurochem 1984 Sep; 43(3):835-40.
     View PubMed
231. Miller LJ, Bartholomew LG, Dozois RR, Dahlin DC. Adenocarcinoma of the rectum arising in a hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Dig Dis Sci 1983 Nov; 28(11):1047-51.
     View PubMed
232. Miller LJ, Reilly WM, Rosenzweig SA, Jamieson JD, Go VLW. A soluble interaction between dibutyryl cyclic guanosine 3':5'-monophosphate and cholecystokinin: a possible mechanism for the inhibition of cholecystokinin activity. Gastroenterology 1983 Jun; 84:1505-1511.
     View PubMed
233. Miller LJ. Small intestinal manifestations of diabetes mellitus. Yale Journal of Biology & Medicine 1983 May-Jun; 56(3):189-93.
     View PubMed
234. McCullough AJ, Miller LJ, Service FJ, Go VL. Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric inhibitory polypeptide. J Clin Endocrinol Metab 1983 Feb; 56(2):234-41.
     View PubMed
235. Rosenzweig SA, Miller LJ, Jamieson JD. Identification and localization of cholecystokinin binding sites on rat pancreatic plasma membranes and acinar cells: a biochemical and morphological study. J Cell Biol 1983; 96:1288-1297.
     View PubMed
236. Miller LJ, Reilly WM, Rosenweig SA, Jamieson JD, Go VLW. The mechanism by which dibutyryl cyclic GMP antagonizes the action of cholecystokinin. Gastroenterology 1983; 84:1637-1639.
     View PubMed
237. Go VL, Miller LJ. The role of gastrointestinal hormones in the control of postprandial and interdigestive gastrointestinal function. Scand J Gastroenterol Suppl 1983; 82:135-42.
     View PubMed
238. Owyang C, Miller LJ, Malagelada JR, Go VL. Nutrient and bowel segment dependency of human intestinal control of gastric secretion. Am J Physiol 1982 Nov; 243(5):G372-6.
     View PubMed
239. Kelly DG, Miller LJ, Malagelada JR, Huizenga KA, Markowitz H. Giant hypertrophic gastropathy (Ménétrier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982 Sep; 83(3):581-9.
     View PubMed
240. Owyang C, Miller LJ, DiMagno EP, Mitchell JC 3rd, Go VL. Pancreatic exocrine function in severe human chronic renal failure. Gut 1982 May; 23(5):357-61.
     View PubMed
241. Rees WD, Malagelada JR, Miller LJ, Go VL. Human interdigestive and postprandial gastrointestinal motor and gastrointestinal hormone patterns. Dig Dis Sci 1982 Apr; 27(4):321-9.
     View PubMed
242. Kelly DG, Miller LJ, Malagelada J-R, Huizenga KA, Markowitz H. Giant hypertrophic gastropathy: Pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982; 83(0):581-9.
     View PubMed
243. Miller LJ, Malagelada JR, Taylor WF, Go VL. Intestinal control of human postprandial gastric function: the role of components of jejunoileal chyme in regulating gastric secretion and gastric emptying. Gastroenterology 1981 Apr; 80(4):763-9.
     View PubMed
244. Miller LJ, Rosenzweig SA, Jamieson JD. Preparation and characterization of a probe for the cholecystokinin octapeptide receptor, N-alpha-125-I-desaminotyrosyl) CCK-8, and its interactions with pancreatic acini. J Biol Chem 1981; 256:12417-12423.
     View PubMed
245. Miller LJ, Malagelada JR, Longstreth GF, Go VL. Dysfunctions of the stomach with gastric ulceration. Dig Dis Sci 1980 Nov; 25(11):857-64.
     View PubMed
246. McGill DB, Miller LJ, Carney JA, Phillips SF, Go VLW, Schutt AJ. Hormonal diarrhea due to pancreatic tumor. Gastroenterology 1980 Sep; 79:571-582.
     View PubMed
247. Miller LJ, Owyang C, Malagelada JR, Gorman CA, Go VL. Gastric, pancreatic, and biliary responses to meals in hyperthyroidism. Gut 1980 Aug; 21(8):695-700.
     View PubMed
248. Miller LJ, Resseguie LJ, Taylor WF, Malagelada JR. Cholecystectomy and gastric ulcer--an etiologic relationship? Mayo Clin Proc 1980 Apr; 55(4):255-7.
     View PubMed
249. Rees WD, Miller LJ, Malagelada JR. Dyspepsia, antral motor dysfunction, and gastric stasis of solids. Gastroenterology 1980 Feb; 78(2):360-5.
     View PubMed
250. Krawisz BR, Miller LJ, DiMagno EP, Go VL. In the absence of nutrients, pancreatic-biliary secretions in the jejunum do not exert feedback control of human pancreatic or gastric function. Journal of Laboratory & Clinical Medicine 1980 Jan; 95(1):13-8.
     View PubMed
251. Owyang C, Miller LJ, DiMagno EP, Brennan LA Jr, Go VL. Gastrointestinal hormone profile in renal insufficiency. Mayo Clin Proc 1979 Dec; 54(12):769-73.
     View PubMed
252. Owyang C, Miller LJ, Lie JT, Fleming CR. Takayasu's arteritis in Crohn's disease. Gastroenterology 1979 Apr; 76:825-828.
     View PubMed
253. Miller LJ, Clain JE, Malagelada JR, Go VL. Control of human postprandial pancreatic exocrine secretion: a function of the gastroduodenal region. Dig Dis Sci 1979 Feb; 24(2):150-4.
     View PubMed
254. Miller LJ, Gorman CA, Go VL. Gut-thyroid interrelationships. Gastroenterology 1978 Nov; 75(5):901-11.
     View PubMed
255. Miller LJ, Malagelada JR, Go VL. Intestinal nutrient influence on the enteroinsular axis. J Clin Endocrinol Metab 1978 Nov; 47(5):1009-14.
     View PubMed
256. Miller LJ, Malagelada JR, Go VL. Postprandial duodenal function in man. Gut 1978 Aug; 19(8):699-736.
     View PubMed
257. Miller LJ, Thistle JL, Payne WS, Gaffey TA, O'Duffy JD. Crohn's disease involving the esophagus and colon. Case report. Mayo Clin Proc 1977 Jan; 52(1):35-8.
     View PubMed
258. Gordon SJ, Miller LJ, Haeffner LJ, Kinsey MD, Kowlessar OD. Abnormal intestinal bile acid distribution in azotemic man: a possible role in the pathogenesis of uremic diarrhea. Gut 1976; 17:58-67.
     View PubMed
259. Miller LJ, Gordon SJ, Haeffner LJ, Saukkonen JJ, Kinsey MD, Kowlessar OD. Bile acid abnormalities in uremic man. Gastroenterology 1974; 66:746.
260. Dong M, Ding XQ, Thomas SE, Gao F, Lam PC, Abagyan R, Miller LJ. Role of lysine (187) within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction. Biochemistry 2007 Apr; 46(15):4522-31.
     View PubMed